Concurrent Presentation of High-Grade Lymphoma and Metastatic Pancreatic Neuroendocrine Tumor 14 Years After Renal Transplant

Trisha Wise-Draper, Julianne Qualtieri, Gautham Mogilishetty, Tahir Latif

Abstract


The development of malignancy, especially lymphoma, is common after solid organ transplant. However, concurrent malignancies are rare and result in a diagnostic and treatment dilemma, particularly in the post-transplant setting. We present a case of a 78-year-old male who was discovered to have a high-grade post-transplant lymphoproliferative disorder (PTLD) and metastatic pancreatic neuroendocrine tumor (PNET) 14 years after kidney transplant. He presented with abdominal pain and at surgical resection was found to have a large small intestine tumor that was consistent with high-grade diffuse large B cell lymphoma. Immune suppression was reduced, and staging workup was completed. Positron emission tomography-computed tomography (PET-CT) showed fluorodeoxyglucose (FDG)-avid metastatic lesions in the liver and a mass in the pancreatic head. Before treatment was initiated, biopsy of a liver lesion revealed metastatic PNET. Due to aggressiveness and potential high mortality of the lymphoma, he was started on rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). After five cycles he developed worsening abdominal pain consistent with progression of the PNET and was placed on everolimus. Here we discuss the complexity of diagnosing concurrent primaries and the treatment of such in the post-transplant setting.




J Hematol. 2014;3(4):112-115
doi: http://dx.doi.org/10.14740/jh180w

Keywords


Cancer; Post-transplant; PNET; PTLD

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Hematology, quarterly, ISSN 1927-1212 (print), 1927-1220 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC BY-NC 4.0)



This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thejh.org    editorial contact: editor@thejh.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
 

© Elmer Press Inc. All Rights Reserved.

IMPORTANT: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!